Suppr超能文献

地榆对幽门螺杆菌感染的体外抗菌活性及网络药理学分析

In vitro anti-bacterial activity and network pharmacology analysis of Sanguisorba officinalis L. against Helicobacter pylori infection.

作者信息

Shen Xue, Zhang Weijia, Peng Chang, Yan Jiahui, Chen Pengting, Jiang Cheng, Yuan Yuemei, Chen Donglian, Zhu Weixing, Yao Meicun

机构信息

School of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou, 510006, China.

School of Pharmaceutical Science (Shenzhen), Sun Yat-Sen University, Guangzhou, 510006, China.

出版信息

Chin Med. 2021 Apr 17;16(1):33. doi: 10.1186/s13020-021-00442-1.

Abstract

BACKGROUND

Helicobacter pylori (H. pylori) infection has become an international public health problem, and antibiotic-based triple or quadruple therapy is currently the mainstay of treatment. However, the effectiveness of these therapies decreases due to resistance to multiple commonly used antibiotics. Sanguisorba officinalis L. (S. officinalis), a traditional Chinese medicine clinically used for hemostasis and treatment of diarrhea, has various pharmacological activities. In this study, in vitro antimicrobial activity was used for the preliminary evaluation of S. officinalis against H. pylori. And a pharmacology analysis approach was also utilized to elucidate its underlying mechanisms against H. pylori infection.

METHODS

Micro-broth dilution method, agar dilution method, checkerboard assay, scanning electron microscopy (SEM), and transmission electron microscopy (TEM) were used for the assessment of anti-bacterial activity. Active ingredients screening, GO analysis, KEGG analysis, construction of PPI network, molecular docking, and RT-qPCR were used to elucidate the underlying pharmacological mechanisms of S. officinalis against H. pylori infection.

RESULTS

The minimum inhibitory concentration (MIC) values of S. officinalis against multiple H. pylori strains including clinically isolated multi-drug resistant (MDR) strains were ranging from 160 to 320 µg/ml. These results showed that S. officinalis had additive interaction with four commonly used antibiotics and could exert antibacterial effect by changing the morphology of bacteria without developing drug resistance. Through network pharmacology analysis, 8 active ingredients in S. officinalis were screened out for subsequent studies. Among 222 putative targets of S. officinalis, 49 targets were identified as potential targets for treatment of H. pylori infection. And these 49 targets were significantly enriched in GO processes such as protein kinase B signaling, protein kinase activity, protein kinase binding, and KEGG pathways such as Pathways in cancer, MicroRNAs in cancer, and TNF signaling pathway. Protein-protein interaction analysis yielded 5 core targets (AKT1, VEGFA, EGFR, SRC, CCND1), which were validated by molecular docking and RT-qPCR.

CONCLUSIONS

Overall, this study confirmed the in vitro inhibitory activity of S. officinalis against H. pylori and explored the possible pharmacological mechanisms, laying the foundation for further research and clinical application.

摘要

背景

幽门螺杆菌(H. pylori)感染已成为一个国际公共卫生问题,目前基于抗生素的三联或四联疗法是主要治疗手段。然而,由于对多种常用抗生素产生耐药性,这些疗法的有效性降低。地榆(Sanguisorba officinalis L.)是一种临床上用于止血和治疗腹泻的传统中药,具有多种药理活性。在本研究中,采用体外抗菌活性对其抗幽门螺杆菌作用进行初步评价,并运用药理学分析方法阐明其抗幽门螺杆菌感染的潜在机制。

方法

采用微量肉汤稀释法、琼脂稀释法、棋盘法、扫描电子显微镜(SEM)和透射电子显微镜(TEM)评估抗菌活性。通过活性成分筛选、基因本体(GO)分析、京都基因与基因组百科全书(KEGG)分析、蛋白质-蛋白质相互作用(PPI)网络构建、分子对接和实时定量聚合酶链反应(RT-qPCR)阐明地榆抗幽门螺杆菌感染的潜在药理机制。

结果

地榆对包括临床分离的多重耐药(MDR)菌株在内的多种幽门螺杆菌菌株的最低抑菌浓度(MIC)值在160至320μg/ml之间。这些结果表明,地榆与四种常用抗生素具有相加作用,可通过改变细菌形态发挥抗菌作用且不会产生耐药性。通过网络药理学分析,筛选出地榆中的8种活性成分用于后续研究。在地榆的222个潜在靶点中,49个靶点被确定为治疗幽门螺杆菌感染的潜在靶点。这些49个靶点在蛋白激酶B信号传导、蛋白激酶活性、蛋白激酶结合等GO过程以及癌症通路、癌症中的微小RNA、肿瘤坏死因子信号通路等KEGG通路中显著富集。蛋白质-蛋白质相互作用分析产生了5个核心靶点(AKT1、VEGFA、EGFR、SRC、CCND1),并通过分子对接和RT-qPCR进行了验证。

结论

总体而言,本研究证实了地榆对幽门螺杆菌的体外抑制活性,并探索了可能的药理机制,为进一步研究和临床应用奠定了基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a64f/8052767/7569c4607e8c/13020_2021_442_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验